600
Participants
Start Date
June 15, 2025
Primary Completion Date
October 18, 2026
Study Completion Date
November 28, 2026
Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes
Farxiga® (dapagliflozin) 10 mg, Onglyza® (saxagliptin) 5 mg, Metformin 500 mg, Oral Mix Prescription Treat type 2 diabetes patients with controlled cancers
China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes
China Import (dapagliflozin) 10 mg, China Import (saxagliptin) 5 mg, Metformin 500 mg, Oral Mix Prescription Treat type 2 diabetes patients with controlled cancers
Medicine Invention Design, Inc. - IORG0007849 - NPI-1023387701, Rockville
UnitedHealthcare
OTHER
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
INDUSTRY